SmartTRAK Life Sciences News and Analysis Blog

2 min read

Navigating Choppy Waters: Q422 Neuromodulation Market Recap

By Anne Staylor on 3/20/23 10:06 AM

While the macro environment is improving, some neuromodulation companies and segments navigated choppy waters in Q422

While the macro environment continued to improve in Q422, the waters remain choppy for some neuromodulation companies and segments. Competitors are making gains on new and differentiated product offerings, strengthening demand and expanding indications. These gains are offset by the residual effects of the pandemic, reimbursement challenges, stubborn inflationary pressures and currency exchange headwinds." For FY22, the spinal cord stimulation (SCS) segment showed signs of recovery by year-end while deep brain stimulation (DBS) slowed on replacement headwinds for some companies.

Among the many topics covered in detail in our comprehensive Q422 Neuromodulation Market Recap* article:

Complete Q422 Neuromodulation Market Overview
SmartTRAK's Expert Market Analysis and Insights
All Company News, Revenues, Data, Charts and Shares
Spinal Cord Stimulation Sees Growth Exiting 2022
Macro Environment Improving
Innovation, Expanding Indications Driving Growth
Potential Payer Headwinds
DBS Slows on Replacement Headwinds, Share Shifts
Q422 Clinical/Regulatory Highlights

Topics: Neuro Therapies Neuromodulation

2 min read

Saluda Medical: Changing the Game in Spinal Cord Stimulation

By Anne Staylor on 3/13/23 9:53 AM

Saluda Medical President and CEO Jim Schuermann discusses the Company, the Evoke System and changing the game in SCS in an interview with SmartTRAK

With the US launch of the Evoke System, Saluda Medical is changing the game in spinal cord stimulation (SCS). At the North American Neuromodulation Society (NANS) Annual meeting in Las Vegas in January, researchers presented impressive 36-month data from the Company’s Evoke Study and the Company was showcasing its Evoke System for the first time on the NANS exhibit hall floor. As the first commercially available closed-loop SCS system using evoked compound action potentials (ECAPs), Evoke is unlike anything on the market. The technology automatically adjusts stimulation to maintain precise and consistent neural activation to the spinal cord for the treatment of intractable low back and leg pain. The Company received FDA PMA for Evoke in February 2022 and announced a limited US commercial release in December 2022, calling it the first and only ‘SmartSCS” in the US.

Saluda Medical President and CEO Jim Schuermann discusses bringing Evoke System to market, the Company’s US launch and commercialization plans, the newest generation of Evoke, his vision for the future and Evoke’s potential impact on the market in an interview with SmartTRAK. Click the button below to download and read a complete transcript of the interview.

Topics: Neuro Therapies Neuromodulation

3 min read

Spotlight on Medtronic Neuromodulation: NANS 2023

By Anne Staylor on 2/10/23 11:40 AM

Medtronic executives Nnamdi Njoku and Charlie Covert discuss Medtronic’s latest initiatives in Neuromodulation in an interview with SmartTRAK at NANS 2023

Nnamdi Njoku, Medtronic’s Senior Vice President and President Neuromodulation, and Charlie Covert, Vice President and General Manager of Pain Therapies, discuss what’s new for Medtronic Neuromodulation, expected market growth in 2023 and strategies for driving growth in spinal cord stimulation (SCS) and deep brain stimulation (DBS) in an interview with SmartTRAK at the North American Neuromodulation Society (NANS) 26^th Annual Meeting held January 12-15, 2023 in Las Vegas, Nevada.

To find out more about the Company’s latest innovations, expanding indications and what’s next for Medtronic Neuromodulation, click on the following video recorded live at NANS 2023. (27:57 minutes.) Specific interview topics by time code are outlined below. A link to download a complete transcript of the interview is also provided below.

Topics: Neuro Therapies Neuromodulation

2 min read

Emerging Technologies in Neurointervention

By Anne Staylor on 1/31/23 9:30 AM

SmartTRAK identifies emerging technologies at the most recent SNIS and ESMINT meetings that have the potential to disrupt the market for neurointervention.

In the market for neurovascular devices, companies continue to innovate and are focusing research and development efforts into novel technologies that could lead to improved outcomes and help fuel growth in the market for ischemic and hemorrhagic stroke devices. At two recent neurointerventional meetings, the Society for NeuroInterventional Surgery (SNIS) 19th Annual meeting and the 14th European Society for Minimally Invasive Neurological Therapy (ESMINT) Congress 2022, SmartTRAK identified emerging technologies that could potentially disrupt the neurovascular market over the next two to five years. This includes enabling technologies for neurointerventional procedures, novel approaches to aspiration for the treatment of acute ischemic stroke (AIS) and innovation in intrasaccular flow disruption devices.

Among the many interesting topics covered in this informative article are:

Enabling Technologies for Neurointervention
- Corindus' CorPath GRX System
- Robotic-assisted Neuroendovascular Navigation
Update on Aspiration
- Cyclical Aspiration
- Modulated Aspiration
Advances in Intrasaccular Flow Disruption Devices

Topics: Neuro Therapies Neurovascular

2 min read

Neuromodulation Trends: SmartTRAK at NANS 2023

By Thomas Wallick on 1/10/23 9:00 AM

SmartTRAK takes a look back at Neuromodulation Trends in 2022 and looks forward to reporting on emerging trends at NANS 2023

Anne Staylor, SmartTRAK's Executive Editor VP & GM, Neuro Therapies, will again be attending and reporting on the North American Neuromodulation Society Annual Meeting (NANS), this year being held in Las Vegas, January 12-15th. If you would like to meet with Anne while at NANS, just click here.

Last year, Anne published a prescient article from the NANS 25th Annual Meeting titled "Neuromodulation Trends in 2022 and Beyond" in which she identified key trends from the meeting in Orlando and provided an outlook of what’s on the horizon for neuromodulation. This included trends in research and technology that will help shape the markets for spinal cord stimulation (SCS), deep brain stimulation (DBS) and peripheral nerve stimulation (PNS), advances in closed-loop therapies, improving care through digital solutions and driving growth through expanding indications.

To download and read the complete "Neuromodulation Trends in 2022 and Beyond" article, just click here.

Topics: Neuro Therapies Neuromodulation

2 min read

Wrestling with Issues and Headwinds: Q322 Neuromodulation Market Recap

By Anne Staylor on 12/29/22 9:30 AM

Growth in the SCS and DBS segments remained soft in Q322 as companies continue to wrestle with macro-environmental issues and currency headwinds

Neuromodulation continued to face a challenging macro environment in Q322 related to stubborn inflationary pressures, currency exchange headwinds and unpredictable surges in COVID affecting supply chains and healthcare staffing in certain geographies. However, some competitors reported seeing steady signs of improvement in the quarter and are looking to expanded indications and new technologies to help drive growth.

Among the many topics covered in detail in our comprehensive Q322 Neuromodulation Market Recap* are:

Topics: Neuro Therapies Neuromodulation

2 min read

Pain Intervention: A Market of Moving Targets

By Shelly Caruso on 9/20/22 9:30 AM

SmartTRAK highlights key movements in the quickly changing landscape of interventional pain management and identifies practice trends surrounding SCS, PNS, minimally invasive spine and SI Joint Fusion from the recent ASPN and INS meetings.

Strong demand for alternatives to narcotic pain management combined with an aging population and growing incidence of chronic pain continue to drive demand for interventional pain techniques. The approach to the treatment of chronic intractable pain is evolving, with a shift toward data-focused treatment optimization, growing use of digital monitoring and holistic evaluation of patient outcomes. Furthermore, increasing overlap among various devices and therapies as well as unclear boundaries between interventional pain, orthopedic and spine practices is spurring physicians to adopt collaborative approaches to patient care.

Among the many timely topics covered in this comprehensive Market Outlook article "Pain Intervention: A Market of Moving Targets", which can be downloaded in its entirety here, are:

Topics: Neuro Therapies Top Story

3 min read

SNIS 2022: Advancing Stroke Research and Innovation

By Anne Staylor on 9/6/22 8:47 AM

SNIS President Michael Chen, MD discusses advancing stroke research and innovation in an interview with SmartTRAK at SNIS 2022.

Michael Chen, MD, the 2022 President of the Society of Neurointerventional Surgery (SNIS) and a neurointerventionalist at Rush University Medical Center in Chicago, discusses advances in stroke care research and innovation in an interview with SmartTRAK at the SNIS 19 ^th Annual meeting held in Toronto, Ontario, Canada July 25-29, 2022.

To find out more about emerging devices for the treatment of hemorrhagic and acute ischemic stroke, advancing the stroke systems of care, physician practice trends and how manufacturers can further innovate to improve care, click on the following video to listen to the interview (23:47 min). A link to download the complete transcript of the interview is also provided below.

Topics: Neuro Therapies

3 min read

Acandis Inc: Targeting the US Market for Neurointervention

By Anne Staylor on 8/23/22 9:00 AM

Georg Schauer, PhD, President of Acandis Inc., discusses the Company, its novel devices and targeting the US market for neurointervention in an interview with SmartTRAK at the Society of Neurointerventional Surgery (SNIS) 19th annual meeting held in Toronto, Canada July 25-26, 2022

To find out more about how Acandis plans to differentiate itself and compete in the US market, click on the following video recorded live at SNIS 2022. (11:30 min). A link to download the complete transcript of the interview is also provided below.

Topics: Neuro Therapies

3 min read

R92 Medical: Reimagining the Road to Stroke Interventions

By Anne Staylor on 8/9/22 9:30 AM

Adam Hattan, VP of Marketing for Route 92 Medical, discusses the Company, its novel system for mechanical thrombectomy and competing in the market for stroke interventions in an interview with SmartTRAK at SNIS 2022.

Amid a growing number of me-too devices, one company that is differentiating itself in the market for stroke thrombectomy is Route 92 Medical (R92). Adam Hattan, R92’s vice president of marketing, discusses R92’s novel system for mechanical thrombectomy and competing in the market for stroke interventions in an interview with SmartTRAK at the Society of Neurointerventional Surgery (SNIS) 19th Annual Meeting held in Toronto, Canada July 25-29, 2022.

To find out more about R92, its Monopoint operating platform and the Company’s strategies for growth, click on the following video recorded live at SNIS 2022. (10:13 min). A link to download a transcript of the interview is also provided below.

Topics: Neuro Therapies Top Story